nausea%20-and-%20vomiting
NAUSEA & VOMITING
Nausea is the sensation felt immediately before vomiting.
Vomiting is a partially voluntary act of forceful expelling of stomach contents up to and out of the mouth that may or may not be preceded by nausea.
Retching or repetitive active contraction of the abdominal muscles occurs between nausea and vomiting.
Management includes correction of clinically relevant metabolic complications, pharmacological therapy and treatment of underlying cause.

Nausea & Vomiting Drug Information

Drug Information

Indication: Vertigo, tinnitus &/or progressive hearing loss associated w/ Meniere's disease & Meniere-like syndrom...

Indication: GI symptoms of functional, non-ulcer dyspepsia (chronic gastritis) ie, sensation of bloating, early satiety, u...

Indication: Symptomatic relief of nausea & vomiting of functional, organic, infectious or dietary origin, induced by r...

Indication: Prophylaxis of migraine w/ or w/o aura. Symptomatic treatment of vestibular vertigo, due to a diagnosed functi...

Indication: Maintenance therapy for symptoms of cerebrovascular origins, labyrinthine & peripheral-circulatory disorde...

Indication: Symptomatic treatment of nausea & vertigo due to Meniere's disease & other labyrinthine disturbances, ...

Indication: Symptomatic relief of allergy or hypersensitivity reactions eg, hay fever, urticaria, angioedema, rhinitis, co...

Indication: GIT & GUT spasm, biliary system spasm & dyskinesia.

Indication: Acute spasm, as in renal or biliary chronic, in radiology for differential diagnosis of obstruction. Reduction...

Indication: Symptomatic treatment of nausea & vertigo due to Meniere's disease & other labyrinthine disturbances, ...

1  /  12
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.